ArticleInvestigational new drugs2021

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Grégoire Marret et al.PubMed ↗Publisher ↗

No numbers read from the abstract.